论文部分内容阅读
目的探讨门静脉插管化疗预防结直肠癌术后肝转移的临床效果。方法将82例行结直肠癌根治手术的患者按化疗方式不同分为2组:治疗组24例,术中门静脉插管将5-FU 15mg.kg-1和MMC 0.1mg.kg-1,溶于150～200mL生理盐水中,经门静脉导管注入,后肝素钠封管,术后10～14d采用5-FU和MMC联合化疗,于门静脉化疗泵注入,每天1次,连用4d,间隔4～5周再进行下一疗程;对照组58例以相同方案行全身化疗。结果治疗组与对照组术后肝转移发生率分别为20.8%(5/24)和50.0%(29/58),2组相比,差异有统计学意义(P<0.05)。结论门静脉插管化疗比全身化疗更有效,可降低肝转移发生率。
Objective To investigate the clinical effect of portal vein chemotherapy in preventing postoperative liver metastasis of colorectal cancer. Methods Eighty-two patients undergoing radical surgery for colorectal cancer were divided into two groups according to different chemotherapy regimens: treatment group (n = 24), intraoperative portal vein catheterization of 5-FU 15 mg.kg-1 and MMC 0.1 mg.kg-1 In 150 ~ 200mL saline, the portal vein catheterization, heparin sealing tube, after 10 ~ 14d with 5-FU and MMC combined with chemotherapy in the portal vein chemotherapy pump injection, once a day, once every 4d, interval 4 ~ 5 Week and then the next course of treatment; control group of 58 patients underwent the same regimen of systemic chemotherapy. Results The incidence of postoperative liver metastases in treatment group and control group were 20.8% (5/24) and 50.0% (29/58), respectively. There was significant difference between the two groups (P <0.05). Conclusion Intravenous catheter chemotherapy is more effective than systemic chemotherapy, can reduce the incidence of liver metastases.